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The studies of recent decades have proved the essen-
tial role of several proteases in growth and development
of the central nerve system. Of great importance is the
system of extracellular proteolysis that, in addition to
zymogene itself and its active form, plasmin, includes
activators of plasminogen (PGn), of urokinase (uPA)
and tissue (tPA) types and inhibitors of these activators
(PAI).
Neuroblastoma ranks second place in the occur-
rence of solid tumors in children. Neuroblastoma cells
secrete uPA, tPA, and PAI (Benjamin et al., 1989b).
uPA is bound to specific receptor (uPAR) and activates
PGn, converting it into PA. PA is implicated in proteol-
ysis and tissue degradation. Highly tumorogenic cells
have enhanced levels of PGn associated with cells (Liu
et al., 1984). PGn itself significantly increases the
migration of neuroblasts (Puglianiello et al., 2000).
0.5 
 
×
 
 10
 
–7
 
 M PGn stimulates the proliferation of neuro-
blastoma cells (Menouny et al., 1997).
Streptokinase (SK) is produced by 
 
β
 
-hemolytic
streptococcus A; C; and G, a representative of human
and animal microflora. It is a strong PGn activator in
non-proteinase pathways. However, the protein proper-
ties and effects have not been well examined.
Since in living systems proteins can not function
individually, there is a high possibility of intermolecu-
lar protein complex formation that will entail changes
in their initial biological activity. It was found that PGn
and SK are able to form stable equimolar complexes
with enzymes of carbohydrate metabolism, in particu-
lar, pyruvate kinase (PK) (Nikandrov et al., 1997).
Experiments in vitro demonstrated that SK modulates
the metabolism and electrophysiological parameters of
nerve cells (Nikandrov et al., 2003c; Romanovskaya,
2005).
The aim of the paper presented is to elucidate the
effect of PGn, SK, and equimolar complexes with PGn
on structural and functional characteristics of human
neuroblastoma IMR-32.
MATERIALS AND METHODS
 
Reagents.
 
 PGn samples isolated from 
 
β
 
-globulin
fractions and purified by affinity chromatography on
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Abstract
 
—The system of extracellular proteolysis consisted of plasminogen (PGn), its active protease, plas-
min, and PGn activators and their inhibitors affect the growth, differentiation, and proliferation of nervous cells
both under normal and pathological conditions. The purpose of our investigation was to study the effects of
exogenous PGn, its activator, streptokinase (SK), pyruvate kinase (PK), and their equimolar complexes on mor-
phological and functional properties of IMR-32 neuroblastoma cells. It has been found that PGn, SK, PK, and
their complexes stimulate cell proliferation during 1–3 days of incubation. We also observed increased DNA,
RNA, and protein content. The low-lactate dehydrogenase (LDH) efflux indicated that the addition of the pro-
teins we assayed to the culture medium prevented the development of degenerative processes caused by serum
deprivation. The levels of extracellular PGn-activator activity, as measured by the fibrinolytic method, increased
in the presence of SK. The SK effect vanished if SK was in the complex with PK on the 3rd day of cultivation.
New original facts were obtained to testify the probability of initiation of neoplastic transformation and tumor
growth potentiation.
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lysine-Sepharose were kindly provided by Dr. N.S. Py-
zhova (Institute of Epidemiology and Microbiology,
Health Ministry, Belarus). The properties of PGn used
in experiments were described previously (Nikandrov
et. al., 1997). PK from rabbit muscle (EC 2.7.1.40) was
purchased from Reanal company (Hungary), SK was
from OAO Belmedpreparat (Belarus), and NADH and
sodium pyruvate was from Sigma-Aldrich (USA).
Other reagents are products from CIS countries.
 
Cell culture.
 
 IMR-32 was obtained from the Russian
Cell Culture Collection (Institute of Cytology, RAS,
St. Petersburg). Cells were cultured in DMEM medium
(Sigma, USA) supplemented with 10% fetal calf serum
(Hyclone, Belgium) and 10 
 
µ
 
g/ml gentamycin at 37
 
°
 
C
in 5% CO
 
2
 
 and 90% humidity. They were subcultured
for 4–5 days each at 90% cell density. For experiments,
cells from nearly confluent cultures were detached from
the vessel surface with EDTA/trypsin mixture (1 : 3) and
plated in a 35-mm Petri dish (Sarstedt, USA) with a
density of 50000 cells per cm
 
2
 
. Cells were grown in
DMEM medium with 10% fetal calf serum for 24 h.
Then the growth medium was replaced by a medium
with 0.5% fetal calf serum. On day 3, the growth
medium was exchanged for the medium without serum
with the addition of PGn, PK, SK, or equimolar PGn–
PK or SK–PK complexes. Control cultures were grown
in serum-free media without additions. Proteins and
their complexes were used in concentrations 10
 
–7
 
, 10
 
–9
 
and 10
 
–11
 
 M. The agents were sterilized by filtration
through 0.22 
 
µ
 
m filters. Equimolar complexes were
prepared immediately before an experiment as
described earlier (Nikandrov et al., 1997). The results
were registered 1 and 3 days after the additions.
 
Cell viability
 
 was estimated with Trypan blue stain-
ing (0.4% solution in phosphate buffer, pH 7.2). The
number of stained (dead) and unstained (viable) cells
were counted in Goryaev’s chamber. The viable cell
fraction was calculated according to the formula 
 
A
 
 =
(
 
B
 
 – 
 
C
 
)/
 
B
 
 
 
×
 
 100%, where 
 
A
 
 is viable cells (%), 
 
B
 
 is total
cell number, and 
 
C
 
 is the number of dead cells. Prolif-
eration index (PI) was calculated as the ratio of final
cell number to the initial (seeded) cell number.
Cell culture medium was put into tubes and centri-
fuged at 150 g for 5 min to sediment nonadhesive cells.
Supernatant was combined with cells detached from
plates by routine technique. Lactate dehydrogenase
(LDH) activity was measured in the culture medium.
 
Determination of DNA, RNA and protein content.
 
Nucleic acid content was determined by the sequential
elimination of the acid-soluble fraction and lipids with
alkaline and acid hydrolysis (Schmidt and
Thannhauser, 1945). Cell pellet was treated with 1 ml
0.3 M HClO
 
4
 
 and placed on ice for 15 min to provide
the complete sedimentation of the acid insoluble frac-
tion. Then the samples were centrifuged at 2000–
3000 g for 10–15 min. The pellet was washed twice
with 0.1 M HClO
 
4
 
 and suspended in 0.5 ml water, after
which 0.5 ml of 0.6 M KOH was added. The tubes were
incubated at 37
 
°
 
C for 1 h and then placed on ice to stop
hydrolysis. Tubes with 2 ml 0.6 M HClO
 
4
 
 added were
kept in ice for 15 min before being centrifuged at 2000–
3000 g for 10 min. Supernatant was used for RNA
determination. 2 ml 0.5 M HClO
 
4
 
 were added to the
pellet. The pellet was resuspended and put in a water
bath at 80
 
°
 
C for 20 min for hydrolysis. DNA content
was determined in these samples. Acid and protein con-
tent were assayed with spectrophotometer CARY-100
(Varian, Australia). The results were calculated by Cary
Win UV software (2003) with RNA/DNA application.
 
LDH activity
 
 in cell culture medium was measured
by the routine spectrophotometric method (Koh and
Choi, 1987). Samples (300 
 
µ
 
l were added to the freshly
prepared substrate–buffer mixture (0.76 mM sodium
pyruvate and 85 
 
µ
 
l NADH in 0.1 M potassium–phos-
phate buffer, pH 7.5) at room temperature. Absorption
of the reaction mixture was measured on the spectro-
photometry at 340 nm for 1 min. NADH reduction was
registered during pyruvate conversion into lactate by
LDH. Enzyme activity was measured as nM NADH at
1 min per 1 mg protein.
PGn-activating cell capacity was assayed by lysis of
fibrin gel with PGn as described previously (Pyzhova et
al., 1996). Fibrin plates were prepared in Petri dishes.
Gel was produced by mixture of 10 ml 0.3% human
fibrinogen in physiological solution and 0.2 ml throm-
bin solution in distilled water. Plates with gel were kept
at room temperature for 2 h, after which samples were
layered on the gel surface. Cells incubated with 10
 
–7
 
 M
tested proteins for 1 or 3 days were washed at 150 g for
5 min. 2 
 
×
 
 10
 
6
 
 washed cells were suspended in fresh
DMEM medium. 30 
 
µ
 
l of suspension was put in plates,
covered with fibrin, and incubated at 37
 
°
 
C. Lysis area
(mm
 
2
 
) was measured after 20 h.
Cells were visualized under the light inverted
phase–contrast microscope (OPTON, Germany), 24 or
72 h after the testing agents were added to the cultures.
 
Statistical analysis.
 
 The results are presented as the
mean value and the standard deviation from no less
than three independent measurements. Statistical sig-
nificance was evaluated by a U-test for nonparametric
samplings. 
 
p
 
 < 0.05 was considered significant. Statis-
tical treatments were done with Statistica 6.0 software.
RESULTS
 
Proliferation and nucleic acid content in IMR-32
cells treated with PGn, PK, SK, or their complexes.
 
10
 
−
 
7
 
–10
 
–9
 
 M PGn in 24 h stimulated metabolism, but
did not affect proliferation. Cell number was unaltered,
but RNA and protein content increased by 38–55% and
27–49%, respectively. 10
 
–7
 
–10
 
–9
 
 M SK augmented
DNA by 34–39%, RNA–24–30%, and protein–43–
45%. Proliferation index (PI) increased by 50% only in
cultures treated with 10
 
–7
 
 M SK. 10
 
–11
 
 M SK or PGn did
not affect cell number and nucleic acid content. In cells
treated with 10
 
–7
 
–10
 
–11
 
 M PGn, RNA and protein con-
 414
 
CELL AND TISSUE BIOLOGY
 
      
 
Vol. 1
 
      
 
No. 5
 
      
 
2007
 
ROMANOVSKAYA, NIKANDROV
 
tent increased by 53–77% and 48–64%, respectively.
Cell number in cultures with 10
 
–7
 
 M PGn was higher
(25%) than in control cultures; however, IP was not
altered. The effect of the equimolar PK–PGn complex
was similar to PGn. The SK–PK complex increased
RNA content by 25–50% and protein by 36–40%. DNA
content and cell number in cultures treated with this com-
plex was similar to those in control cultures (Table 1).
Suppression of metabolism and inhibition of cell
proliferation was observed in neuroblastoma cultures
grown in serum-free medium for 3 days. DNA and pro-
tein content were unchanged, whereas RNA content
was reduced to 50%. These results are presumably
explained by the high metabolism rate of the tumor cell
and the requirements for nutrients and growth factors of
fetal calf serum. PGn in each concentration induced an
increase in DNA content by 21–61%, RNA by 71–
118%, and protein by 38–88%. In comparison with the
control, PGn sustained cell proliferation and PI
increased by 45–91%. SK also supported IMR-32 cell
viability. SK treatment for 3 days augmented DNA con-
tent by 41–185%, RNA by 41–90%, and protein by 53–
145%. IP increased by 54–154%. 10
 
–11
 
 SK did not
affect the RNA amount, which was comparable with
the amount found after 1 day of cultivation. The addi-
tion of PK in any concentration to the culture medium
resulted in an increase in DNA content by 132–281%,
RNA by 171–231%, protein by 154–273%, and IP by
154–273%. 10
 
–7
 
 M PGn–PK complex enlarged the con-
tent of DNA by 93%, RNA by 289%, protein by
152%, and IP by 191%. Lower complex concentra-
tion, 10
 
–9
 
 M, slightly influenced the DNA amount,
whereas RNA content was enhanced by 213%, protein
by 119% and IP by 127%. 10
 
–11
 
 complex raised the
RNA amount by 100%; other parameters were
unchangeable. In 3 days, the PK–SK complex
increased the content of RNA by 95–206%, DNA by
102% (only in 10
 
–7
 
 M concentration), and protein by
40–150%. Macromolecule content in cells cultivated
with 10
 
–9
 
 and 10
 
–11
 
 complexes for 1 and 3 days were
comparable.10
 
–7
 
 and 10
 
–11
 
 M complex increased IP by
45–154% (Table 2).
Free or complex bound proteins apparently have dif-
ferent effects on nucleic acid and protein content, as
 
Table 1. 
 
 Nucleic acid content and proliferation in human neuroblastoma IMR-32 cells treated with pyruvate kinase (PK),
plasminogen (PGn), streptokinase (SK), or their equimolar PGn–PK or SK–PGn complexes after 1-day cultivation
Agent concentration,
M
Content, mg/ml (
 
X
 
 
 
± 
 
S
 
x
 
)
IP
RNA DNA Protein
Control 4.3 
 
±
 
 0.32 3.25 
 
±
 
 0.7 64.72 
 
±
 
 6.79 1.2 
 
±
 
 0.2
 Pyruvate kinase
10
 
–7
 
7.63 
 
±
 
 0.24
 
a
 
4.36 
 
±
 
 0.73 106.06 
 
±
 
 2.52
 
a
 
1.5 
 
±
 
 0.1
10
 
–9
 
6.92 
 
±
 
 0.36
 
a
 
4.28 
 
±
 
 1.53 97.14 
 
±
 
 16.0
 
a
 
1.3 
 
±
 
 0.2
10
 
–11
 
6.58 
 
±
 
 1.37
 
a
 
4.04 
 
±
 
 0.78 95.64 
 
±
 
 2.85
 
a
 
1.2 
 
±
 
 0.1
Plasminogen
10
 
–7
 
5.93 
 
±
 
 0.56
 
a
 
4.43 
 
±
 
 0.58 82.08 
 
±
 
 2.58
 
a
 
1.6 
 
±
 
 0.3
10
 
–9
 
6.69 
 
±
 
 0.76
 
a
 
3.65 
 
±
 
 0.61 96.65 
 
±
 
 10.25
 
a
 
1.3 
 
±
 
 0.2
10
 
–11
 
5.24 ± 0.61 3.94 ± 0.56 80.65 ± 4.62a 1.2 ± 0.2
Plasminogen–Pyruvate kinase
10–7 5.94 ± 0.79a, c 3.94 ± 0.88 96.52 ± 5.12a, b 1.5 ± 0.1
10–9 5.29 ± 0.12a, b 3.73 ± 0.25 86.31 ± 1.04a 1.3 ± 0.1
10–11 5.31 ± 0.74 3.41 ± 0.06 87.72 ± 6.65a 1.3 ± 0.2
Streptokinase
10–7 5.64 ± 0.09a 4.53 ± 0.46a 93.56 ± 3.94a 1.8 ± 0.3a
10–9 5.33 ± 0.37a 4.37 ± 0.25a 92.9 ± 4.72a 1.5 ± 0.2
10–11 5.5 ± 1.03 3.89 ± 0.5 87.97 ± 0.54a 1.2 ± 0.2
Streptokinase–Pyruvate kinase
10–7 6.48 ± 0.21a, b 3.06 ± 0.31 90.69 ± 5.36a, c 1.2 ± 0.1
10–9 6.18 ± 0.65a 2.95 ± 0.89 88.21 ± 11.93a 1.1 ± 0.1
10–11 5.39 ± 0.55a 3.01 ± 0.4 91.54 ± 8.18a 1.1 ± 0.2
a
 The difference with control is significant.
b
 The difference between equimolar complex and agents they are composed is significant.
c
 The difference from PGn equimolar concentration is significant. Statistical comparison was made by Mann–Whitney test for nonparamet-
ric samples (p < 0.05).
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well as on cell proliferation. Thus, IMR-32 cells incu-
bated with PGn, PK, or a PGn–PK complex for 1 day
had increased RNA and protein content. The amount of
these biomolecules in cells grown with 10–7 M PK was
higher than in cells cultivated with PGn or PK–PGn.
DNA concentration in cells incubated with PK or
equimolar SK–PK complex was similar to control cells,
whereas 10–7–10–9 M SK induced an enlarged amount
RNA, DNA, and protein, as well as stimulated prolifer-
ation.
In 3 days, RNA content in cells cultivated with 10–7
M PGn–PK complex was comparable with that in cells
grown with 10–7 M PK and higher than in cells incu-
bated with the same dose of PGn. The DNA amount in
cultures with the complex did not differ from that in
cells cultivated with PGn. Protein content was higher
than in cells incubated with PGn but lower than in cells
treated with PK. IP was lower than in PK treated cul-
tures but higher than in PGn cultures. 10–7 M SK–PK
complex induced cell RNA higher than with SK alone.
Other characteristics were similar to those observed in
cultures with SK but different from those induced by
PGn (Tabl.2).
Effects of PGn, PK, SK, PGn–PK, and SK–PK on
cell viability and extracellular LDH activity. Cell via-
bility in treated and control cultures was 90–98% for
1 day. In 3 days, cell viability in control fell down to
35%. In treated cells, viability was 80–98%, depending
on the agent and its concentration.
Increased LDH activity in the culture medium was
registered in the control after 24 h. In 3 days, it was
enhanced by a factor of 5, whereas in cultures with
added agents, extracellular LDH activity was
reduced during the entire period of observation,
except for 10–11 M PGn, which did not reduce LDH
activity more than in control cultures. In 3 days, LDH
activity in cultures with 10–7 M PGn and its complex
with PK was higher than in cultures with PK, SK or
their complex. Other differences in extracellular LDH
activity in treated cultures were not recorded (Fig. 1).
IMR-32 cell morphology in cultures with PGn, PK,
SK, or their equimolar complexes. Most of the cells in
the control cultures were floating or round with either
Table 2.  Nucleic acid content and proliferation in human neuroblastoma IMR-32 cells treated with pyruvate kinase (PK),
plasminogen (PGn), streptokinase (SK) or their equimolar PGn–PK or SK–PGn complexes after 3-day cultivation
Agent concentration,
M
Content, mg/ml (X ± Sx) IP
RNA DNA Protein
Control 2.87 ± 0.11 3.37 ± 0.2 56.39 ± 3.25 1.1 ± 0.1
 Pyruvate kinase
10–7 9.51 ± 0.57a 12.85 ± 2.28a 203.7 ± 17.26a 4.1 ± 0.3a
10–9 9.31 ± 0.43a 12.3 ± 1.73a 198.91 ± 17.82a 3.9 ± 0.1a
10–11 7.77 ± 1.65a 7.82 ± 3.43a 141.88 ± 45.63a 2.8 ± 0.2a
Plasminogen
10–7 6.25 ± 1.06a 4.74 ± 0.97a 92.55 ± 9.61a 1.8 ± 0.1a
10–9 6.55 ± 1.66a 5.42 ± 1.57a 105.94 ± 26.95a 2.1 ± 0.1a
10–11 4.91 ± 0.38a 4.09 ± 0.86 78.05 ± 10.36a 1.6 ± 0.2a
Plasminogen–Pyruvate kinase
10–7 11.42 ± 1.59a, d 6.5 ± 2.85a, c 142.3 ± 33.79a, b 3.2 ± 0.3a, b
10–9 8.99 ± 0.87a 4.2 ± 0.68 123.59 ± 11.75a, c 2.5 ± 0.3a, c
10–11 5.75 ± 1.36a 2.48 ± 1.12 75.39 ± 13.38 1.5 ± 0.3
Streptokinase
10–7 5.47 ± 1.22a 9.62 ± 1.07a 138.42 ± 15.5a 2.8 ± 0.1a
10–9 4.06 ± 1.02a 5.75 ± 0.67a 90.57 ± 5.01a 1.8 ± 0.2a
10–11 3.07 ± 0.11 4.74 ± 0.69a 86.06 ± 6.08a 1.7 ± 0.2a
Streptokinase–Pyruvate kinase
10–7 8.78 ± 0.62a, e 6.83 ± 2.0a, c 141.3 ± 14.3a, c 2.8 ± 0.2a, c
10–9 6.8 ± 2.03a, c 3.39 ± 0.33 90.52 ± 18.22a, c 1.8 ± 0.2a, c
10–11 5.6 ± 0.49a, c 3.11 ± 0.12 79.07 ± 4.56a, c 1.6 ± 0.2a, c
a
 The difference with control is significant.
b
 The difference between equimolar complex and agents they are composed is significant.
c
  The difference from PGn equimolar concentration is significant. Statistical comparison was made by Mann–Whitney test for nonpara-
metric samples (p < 0.05).
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no or short processes. In cultures grown with 10–7 M
PGn, cells produced a monolayer. Floating or round
cells were of rare occurrence. Differentiated cells with
long processes (more than 50 µm) were observed. In
cultures grown with SK for 3 days more round cells
with short processes were seen than in cultures treated
with PGn. The SK–PK complex prevented destructive
events more effectively than SK alone. In cultures
treated with 10–7 M PK or PGn–PK cells developed a
dense monolayer and floating cells were not observed
(Fig. 2).
PGn, PK, SK, and their equimolar complex effect on
the PGn-activating function of IMR-32 neuroblastoma
cells. It is known that neuroblastoma cells secrete
2 PGn activators, uPA, and tPA (Benjamin et al., 1989;
Seeger et al., 1977). We have examined how the PGn
activating capacity of neuroblastoma cells treated with
agents changed during different periods. It was shown
that cells in cultures grown with PK and PGn or their
complex sustain the ability to activate PGn. SK stimu-
lated the cell capacity of PGn activation; it was 3 times
higher after 1 day and 6 times higher after 6 days. SK–
PK complex induced the enlargement of the lysis zone
by a factor of 2.7 after 1 day, but later, the cultures were
similar to control cultures (Table 3).
DISCUSSION
The plasminogen–plasmin system plays a key role
in the regulation of cell proliferation and migration in
embryogenesis tumor invasion and metastasis (Dana et
al., 1985; Valinsky, Le Douarin, 1985). The paper pre-
sented confirmed the implication of the system in vital
functions of human neuroblastoma. Cells cultivated
with PGn had an increased content of DNA, RNA, and
protein. Cell number and proliferation index were also
higher than in control cultures. The findings show that
the agents stimulate the proliferation of neuroblastoma
cells. It was previously reported that the mitogenic
action of PGn is abolished by a receptor inhibitor of the
insulin-like growth factor and antibodies to IGF2(Menouny et al., 1997). It is probable that PGn action is
mediated via IGFs. For neuroblastoma cells, it is IGF2
as it is produced by these cells (El-Badry et al., 1989).
The influence of IGFs on cell proliferation is well rec-
ognized (El-Badry et al., 1991). It was demonstrated
that neurons express surface α-enolase, which is a PGn
receptor (Nakagima and Hamanoue, 1994). It is unclear
whether neuroblastoma cells have α-enolase on their
surface, but it is well known that they express amphot-
erin. PGn, as well as tPA, is able to complex with
amphoterin via lysine-binding sites and its binding
leads to the acceleration of PGn activation (Parkkinen
and Rauvala, 1991). Activated PGn is able to affect cell
microenvironment, in particular to cause IGF2 activa-
tion. Moreover, extracellular LDH activity was lower in
cultures with PGn, indicating that PGn is able to pre-
vent membrane injury and cell death. This is confirmed
by the findings on cell viability. The data are in agree-
ment with the results we obtained earlier with rat pheo-
chromocytoma PC12 that 10–6–10–7 M PGn improved
cell viability in serum-free cultures (Nikandrov et al.,
2002). Taking into account that cell death in a serum-
free medium is induced by the activation of free radi-
cals (Sokolova et al., 2005), we assume that the PGn
property of weak superoxide convergence (Nikandrov
and Pyzhova, 2003b) prevents oxidative stress under
serum deprivation.
We were the first to examine the influence of SK, a
PGn activator, on neuroblastoma cells. SK facilitates
cell viability and proliferation in serum-deficient
media. Our previous study showed that SK affected
neuronal cells directly, i.e., omitting the blood stream.
It allows us to consider SK to be a regulator protein.
The SK effect depends on the cell type, particularly tis-
sue differentiation. It is highly probable that SK is a
trigger and stabilizes the cell structure and function. As
a result, cells stay viable under unfavorable conditions.
PGn
15
PGn-PK C PK SK SK-PK
(b)
0
30
45
2
(a)
0
6
10
***
*
*
*
*
**
4
8
12
LDH Activity
*
*
*
*
*
Control
10–7 M
10–9 M
10–11 M
Fig. 1. LDH activity in culture medium of human neuro-
blastoma IMR-32 cells after 1 (a) and 3 (b) days of cultiva-
tion with PGn, SK, PK, or their equimolar complexes.
LDH activity is determined as nM NADH per min per 1 mg
protein; (*) the difference between control and experimen-
tal groups are significant; (**) the difference between PGn
and other agents is significant. The difference is determined
by Mann–Whitney criteria (p < 0.05).
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PK simulated cell proliferation even more than PGn
or SK. PK influence depends on the cell type. Thus, it
was found earlier that PK (10–7 M, in particular) inhib-
ited the cell growth of rat glioma C6 (Romanovskaya,
2005).
The mechanisms underlying SK or PK regulation of
cell viability and proliferation in nanomolar concentra-
tions is still unclear. It seems unlikely that proteins dis-
integrated in growth media may be a supply of amino
acids for cells, as the amount of the proteins added to
cultures is very low. Most likely, the proteins are bound
with some surface structures (receptors) responsible for
cell proliferation. However, a nonreceptor pathway
cannot be excluded. Thus, taking into consideration
that even a low (10–11 M) concentration of PGn or SK
enhanced the DNA, RNA, and protein content, as well
as stimulated cell proliferation in 3-day cultivation, it is
possible to suggest that the mechanisms underlying the
protein action are based on transmembrane ion
(a) (b)
(c) (d)
(e) (f)
Fig. 2. IMR-32 cell growth in a serum-free medium (a) and in a medium with 10–7 M agents (b–f). (b) PK; (c) PGn; (d) PGn–PK
equimolar complex; (e) SK; (f) equimolar SK–PGn complex. Phase contrast; ob. 16×.
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exchanges, particularly Ca2+ ions. Further investiga-
tions will clarify the problem.
Thus, we obtained new facts on the initiation of cell
malignization and tumor growth.
The work is supported by grant from Presidium of
NAN, Belarus (no. 2006324).
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